Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study.
| Autor: | Krymchantowski A; Headache Center of Rio, Rio de Janeiro, Brazil., Jevoux C; Headache Center of Rio, Rio de Janeiro, Brazil., Krymchantowski AG; Headache Center of Rio, Rio de Janeiro, Brazil., Silva-Néto RP; Federal University of the Parnaíba Delta, Parnaíba, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical neuropharmacology [Clin Neuropharmacol] 2023 Sep-Oct 01; Vol. 46 (5), pp. 181-185. Date of Electronic Publication: 2023 Jun 20. |
| DOI: | 10.1097/WNF.0000000000000559 |
| Abstrakt: | Objective: Medication overuse headache (MOH) in chronic migraineurs may be a cause or consequence of the overuse of symptomatic medications for headache attacks. It is highly prevalent in tertiary centers. We compared the efficacy of 3 anti-CGRP monoclonal antibodies with traditional pharmacological agents in patients with chronic migraine (CM) and MOH. Methods: A randomized, cross-sectional, prospective, and open trial with real-world comparison groups was carried out. The sample consisted of 100 consecutive patients having CM and MOH. Results: Eighty-eight patients (65 women and 23 men) were included in the study and divided into 4 groups: those having used erenumab (19.3%), galcanezumab (29.6%), fremanezumab (25%) and conventional medications, and the control group (26.1%). Ages ranged from 18 to 78 years (mean, 44.1 ± 13.6 years). In the 6 months of follow-up, there was a significant reduction in the number of headache days in the 3 groups when compared with the control ( P < 0.0001). Conclusions: The small number of patients included in each group and the open design do not allow definitive conclusions, but the use of anti-CGRP monoclonal antibodies in patients with CM and MOH may result in lessening the number of headache days when compared with conventional treatment with drugs. Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|